Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

1.450 -0.040 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Geron Stock Is Soaring After Hours: What's Going On?
Geron shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic drugs advisory committee (ODAC) voted in favor of the... 
Via Benzinga
Why Geron Stock Is Falling Today
Geron shares are trading lower Tuesday after a Reuters report stated FDA staff reviewers raised multiple safety concerns over Geron's anemia drug, imetelstat. According to the report, FDA staff said... 
Via Benzinga
Exposures Product Safety
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment
The FDA's review of Geron Corporation's imetelstat application for anemia in lower-risk MDS patients. Expert analysis suggests a favorable AdComm vote and potential full FDA approval by the June 16,... 
Via Benzinga
Exposures Product Safety
Geron Earnings Preview
Via Benzinga
Geron (GERN) Q2 2023 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Geron (GERN) Q1 2023 Earnings Call Transcript
GERN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Geron (GERN) Q4 2023 Earnings Call Transcript
GERN earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Recap: Geron Q1 Earnings
Via Benzinga
A Preview Of Geron's Earnings
Via Benzinga
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
7 Stocks to Buy if You Anticipate a Hot November
Although the weather might be chilly, a hot November happens to be a recurring theme, which may boost these stocks to buy. 
Via InvestorPlace
Geron (GERN) Q3 2023 Earnings Call Transcript
GERN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
7 Must-Own Small-Cap Stocks That Could Outperform the Market
If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you. 
Via InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p 
Via Benzinga
Why Is Geron (GERN) Stock Up Today?
Geron (GERN) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares from Goldman Sachs. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
Exposures Product Safety
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
What's Going On With Geron Stock Today
Geron Corporation (NASDAQ: GERN) submitted a marketing application with the FDA seeking approval for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to... 
Via Benzinga
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Geron Are Up 30% This Week
The company's CEO was scheduled to speak at a virtual conference on Thursday. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.